

Florian Scherer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2219967/publications.pdf>

Version: 2024-02-01

31
papers

6,126
citations

471509

17
h-index

526287

27
g-index

35
all docs

35
docs citations

35
times ranked

9744
citing authors

#	ARTICLE	IF	CITATIONS
1	Determining cell type abundance and expression from bulk tissues with digital cytometry. <i>Nature Biotechnology</i> , 2019, 37, 773-782.	17.5	2,396
2	Integrated digital error suppression for improved detection of circulating tumor DNA. <i>Nature Biotechnology</i> , 2016, 34, 547-555.	17.5	837
3	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017, 7, 1394-1403.	9.4	701
4	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016, 7, 11815.	12.8	520
5	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. <i>Science Translational Medicine</i> , 2016, 8, 364ra155.	12.4	348
6	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2845-2853.	1.6	313
7	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. <i>Blood</i> , 2015, 125, 3679-3687.	1.4	270
8	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , 2021, 39, 1537-1547.	17.5	151
9	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , 2019, 178, 699-713.e19.	28.9	138
10	T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. <i>Nature Communications</i> , 2022, 13, 925.	12.8	104
11	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. <i>Blood</i> , 2017, 130, 440-452.	1.4	66
12	Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer. <i>Molecular Oncology</i> , 2022, 16, 527-537.	4.6	42
13	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2605-2616.	1.6	37
14	High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. <i>Blood Advances</i> , 2020, 4, 3378-3381.	5.2	34
15	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. <i>Cancers</i> , 2021, 13, 1151.	3.7	27
16	Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention. <i>Cancer Cell</i> , 2019, 36, 250-267.e9.	16.8	25
17	Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation. <i>Leukemia and Lymphoma</i> , 2016, 57, 151-160.	1.3	16
18	Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling. <i>Recent Results in Cancer Research</i> , 2020, 215, 213-230.	1.8	15

#	ARTICLE	IF	CITATIONS
19	Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma. <i>Blood</i> , 2021, 138, 6-6.	1.4	15
20	Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis. <i>British Journal of Haematology</i> , 2020, 190, e110-e114.	2.5	10
21	Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management. <i>Diagnostics</i> , 2020, 10, 550.	2.6	8
22	Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1089-1089.	1.4	8
23	Stringent Base Specific and Optimization-Free Multiplex Mediator Probe ddPCR for the Quantification of Point Mutations in Circulating Tumor DNA. <i>Cancers</i> , 2021, 13, 5742.	3.7	3
24	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 755-757.	1.6	2
25	Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage. <i>Blood</i> , 2020, 136, 30-31.	1.4	2
26	Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis. <i>Blood</i> , 2021, 138, 709-709.	1.4	1
27	Noninvasive Cancer Classification Using Diverse Genomic Features in Circulating Tumor DNA. , 2016, , .		0
28	Quantitative Analysis of AID Expression and Somatic Hypermutation Identifies Isotype-Switched and Non-Switched Follicular Lymphomas As Distinct Biological Subgroups. <i>Blood</i> , 2011, 118, 3666-3666.	1.4	0
29	Aid-Mediated Hypermutation of B-Cell Receptors with Subsequent Subclone Selection Define Biological Differences Between IgM-Expressing and Isotype-Switched Follicular Lymphoma. <i>Blood</i> , 2012, 120, 680-680.	1.4	0
30	B-Cell Receptor Selection Pattern and Natural History Of Follicular Lymphoma. <i>Blood</i> , 2013, 122, 4258-4258.	1.4	0
31	Change is Coming: Plan S From the Early Career Scientist Perspective. <i>HemaSphere</i> , 2020, 4, e500.	2.7	0